Remnant Lipoproteins from Patients with Sudden Cardiac Death Enhance Coronary Vasospastic Activity Through Upregulation of Rho-Kinase

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 5, 2004, Pages 918-922

  Oi, Keiji ^a   Shimokawa, Hiroaki ^a,b   Hiroki, Junko ^a   Uwatoku, Toyokazu ^a   Abe, Kohtaro ^a   Matsumoto, Yasuharu ^a   Nakajima, Yasuhiro ^c   Nakajima, Katsuyuki ^d   Takeichi, Sanae ^c   Takeshita, Akira ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Japan Immunoresearch Institute   (Japan)

Author keywords

Coronary vasospasm; Lipoproteins; Sudden cardiac death

Indexed keywords

ENZYME INHIBITOR; HYDROXYFASUDIL; LIPOPROTEIN; RHO KINASE; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY SPASM; ENZYME ACTIVITY; HEART DEATH; HUMAN; HUMAN CELL; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SUDDEN DEATH; SWINE; VASCULAR SMOOTH MUSCLE;

ADULT; AGED; ANIMALS; CELLS, CULTURED; CORONARY VASOSPASM; DEATH, SUDDEN, CARDIAC; ENZYME INDUCTION; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPOPROTEINS; MALE; MIDDLE AGED; PROTEIN-SERINE-THREONINE KINASES; SEROTONIN; SINGLE-BLIND METHOD; SWINE; VASOCONSTRICTION;

EID: 2442461182     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000126678.93747.80     Document Type: Article

References (31)

1. Demirovic J, Myerburg RJ. Epidemiology of sudden coronary death: an overview. Prog Cardiovasc Dis. 1994;37:39-48.
2. Takeichi S, Nakajima Y, Yukawa N, Saito T, Seto Y, Huang XL, Kusakabe T, Jin ZB, Hasegawa I, Nakano T, Saniabadi A, Adachi M, Ohara N, Wang T, Nakajima K. Plasma triglyceride-rich lipoprotein remnants as a risk factor of Pokkuri disease. Leg Med (Tokyo). 2001;3: 84-94.
3. Myerburg RJ, Kessler KM, Mallon SM, Cox MM, deMarchena E, Interian A, Jr., Castellanos A. Life-threatening ventricular arrhythmias in patients with silent myocardial ischemia due to coronary-artery spasm. N Engl J Med. 1992;326:1451-1455.
4. Igarashi Y, Tamura Y, Suzuki Y, Tanabe Y, Yamaguchi T, Fujita T, Yamazoe M, Aizawa Y, Shibata A. Coronary artery spasm is a major cause of sudden cardiac arrest in survivors without underlying heart disease. Coron Artery Dis. 1993;4:177-185.
5. Miller DD, Waters DD, Szlachcic J, Theroux P. Clinical characteristics associated with sudden death in patients with variant angina. Circulation. 1982;66:588-592.
6. Campos E, Nakajima K, Tanaka A, Havel RJ. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res. 1992;33:369-380.
7. Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada N, Nakamura H, Campos E, Havel RJ. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta. 1993;223:53-71.
8. McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PW, Ordovas JM, Schaefer EJ. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis. 2001;154:229-236.
9. Kugiyama K, Doi H, Takazoe K, Kawano H, Soejima H, Mizuno Y, Tsunoda R, Sakamoto T, Nakano T, Nakajima K, Ogawa H, Sugiyama S, Yoshimura M, Yasue H. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation. 1999;99:2858-2860.
10. Takeichi S, Yukawa N, Nakajima Y, Osawa M, Saito T, Seto Y, Nakano T, Saniabadi AR, Adachi M, Wang T, Nakajima K. Association of plasma triglyceride-rich lipoprotein remnants with coronary atherosclerosis in cases of sudden cardiac death. Atherosclerosis. 1999;142:309-315.
11. Sakata K, Miho N, Shirotani M, Yoshida H, Takada Y, Takada A. Remnant-like particle cholesterol is a major risk factor for myocardial infarction in vasospastic angina with nearly normal coronary artery. Atherosclerosis. 1998;136:225-231.
12. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol. 2002;39:319-327.
13. Shimokawa H. Cellular and molecular mechanisms of coronary artery spasm: lessons from animal models. Jpn Circ J. 2000;64:1-12.
14. Shimokawa H, Ito A, Fukumoto Y, Kadokami T, Nakaike R, Sakata M, Takayanagi T, Egashira K, Takeshita A. Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. J Clin Invest. 1996;97:769-776.
15. Kandabashi T, Shimokawa H, Miyata K, Kunihiro I, Kawano Y, Fukata Y, Higo T, Egashira K, Takahashi S, Kaibuchi K, Takeshita A. Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1beta. Circulation. 2000;101:1319-1323.
16. Morishige K, Shimokawa H, Eto Y, Kandabashi T, Miyata K, Matsumoto Y, Hoshijima M, Kaibuchi K, Takeshita A. Adenovirus-mediated transfer of dominant-negative rho-kinase induces a regression of coronary arteriosclerosis in pigs in vivo. Arterioscler Thromb Vasc Biol. 2001;21: 548-554.
17. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation. 2002;105:1545-1547.
18. Ohara N, Takeichi S, Naito Y, Nakajima Y, Yukawa N, Nakano T, Nakajima K. Remnant-like particles from subjects who died of coronary artery disease suppress NO synthase activity and attenuate endothelium-dependent vasorelaxation. Clin Chim Acta. 2003;338:151-156.
19. Oshiro N, Fukata Y, Kaibuchi K. Phosphorylation of moesin by rho-associated kinase (Rho-kinase) plays a crucial role in the formation of microvilli-like structures. J Biol Chem. 1998;273:34663-34666.
20. Fukata Y, Kimura K, Oshiro N, Saya H, Matsuura Y, Kaibuchi K. Association of the myosin-binding subunit of myosin phosphatase and moesin: dual regulation of moesin phosphorylation by Rho-associated kinase and myosin phosphatase. J Cell Biol. 1998;141:409-418.
21. Ichiki T, Usui M, Kato M, Funakoshi Y, Ito K, Egashira K, Takeshita A. Downregulation of angiotensin II type 1 receptor gene transcription by nitric oxide. Hypertension. 1998;31:342-348.
22. Kugiyama K, Doi H, Motoyama T, Soejima H, Misumi K, Kawano H, Nakagawa O, Yoshimura M, Ogawa H, Matsumura T, Sugiyama S, Nakano T, Nakajima K, Yasue H. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation. 1998;97:2519-2526.
23. Kawakami A, Tanaka A, Nakajima K, Shimokado K, Yoshida M. Atorvastatin attenuates remnant lipoprotein-induced monocyte adhesion to vascular endothelium under flow conditions. Circ Res. 2002;91:263-271.
24. Kawakami A, Tanaka A, Chiba T, Nakajima K, Shimokado K, Yoshida M. Remnant lipoprotein-induced smooth muscle cell proliferation involves epidermal growth factor receptor transactivation. Circulation. 2003;108:2679-2688.
25. Twickler TB, Dallinga-Thie GM, Visseren FL, de Vries WR, Erkelens DW, Koppeschaar HP. Induction of postprandial inflammatory response in adult onset growth hormone deficiency is related to plasma remnant-like particle-cholesterol concentration. J Clin Endocrinol Metab. 2003;88:1228-1233.
26. Cohn JS, Marcoux C, Davignon J. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler Thromb Vasc Biol. 1999;19:2474-2486.
27. Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med. 1999;246:341-355.
28. Bjorkegren J, Silveira A, Boquist S, Tang R, Karpe F, Bond MG, de Faire U, Hamsten A. Postprandial enrichment of remnant lipoproteins with apoC-I in healthy normolipidemic men with early asymptomatic atherosclerosis. Arterioscler Thromb Vasc Biol. 2002;22:1470-1474.
29. Bischoff A, Czyborra P, Fetscher C, Meyer Zu Heringdorf D, Jakobs KH, Michel MC. Sphingosine-1-phosphate and sphingosylphosphorylcholine constrict renal and mesenteric microvessels in vitro. Br J Pharmacol. 2000;130:1871-1877.
30. Tosaka M, Okajima F, Hashiba Y, Saito N, Nagano T, Watanabe T, Kimura T, Sasaki T. Sphingosine 1-phosphate contracts canine basilar arteries in vitro and in vivo: possible role in pathogenesis of cerebral vasospasm. Stroke. 2001;32:2913-2919.
31. Shirao S, Kashiwagi S, Sato M, Miwa S, Nakao F, Kurokawa T, Todoroki-Ikeda N, Mogami K, Mizukami Y, Kuriyama S, Haze K, Suzuki M, Kobayashi S. Sphingosylphosphorylcholine is a novel messenger for Rho-kinase-mediated Ca2+ sensitization in the bovine cerebral artery: unimportant role for protein kinase C. Circ Res. 2002; 91:112-119.